Investors looking for biotechnology exposure often compare two distinct options: the ALPS Medical Breakthroughs ETF (SBIO) and the SPDR S&P Biotech ETF (XBI). Both are passive ETFs focused on U.S.-listed biotech and pharmaceutical companies, yet they follow quite different approaches. SBIO screens for clinical-stage companies in a smaller, market-cap-weighted universe, while XBI delivers equal-weighted coverage across a wider range of the sector. The choice comes down to aligning each fund’s construction with specific investment objectives.
SBIO tracks the S-Network Medical Breakthroughs Index with a clinical focus. Holdings must have drug candidates in Phase II or Phase III FDA trials and market caps typically between $200 million and $5 billion. The fund holds about 90 stocks and weights them by market cap, so larger names within that group carry more influence. Recent top holdings have included CRNX, APGE, CGON, DNTH, and ORKA. Exposure is almost entirely in biotechnology and pharmaceuticals. The expense ratio stands at 0.50%, and the fund launched in December 2014. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
XBI follows the S&P Biotechnology Select Industry Index on a modified equal-weighted basis. No single holding dominates, with each typically around 1–3% of assets. The fund includes roughly 166 stocks that range from large-cap established names to smaller developers. Representative holdings include MRNA, TWST, NTRA, ABBV, UTHR, AMGN, and BIIB. Sector allocation is nearly all biotechnology. XBI’s expense ratio is 0.35%, and it has traded since January 2006, which supports its deeper liquidity profile.
Both ETFs operate in a sector supported by long-term drivers such as demographic trends, ongoing M&A activity, and a pipeline of FDA approvals in areas like oncology and rare diseases. Interest-rate expectations matter because many clinical-stage firms rely on external capital and are valued on distant cash flows. Regulatory shifts, drug-pricing discussions, and patent expirations at larger pharma companies also shape sentiment. The main risk remains binary clinical-trial results that can drive sharp moves in individual holdings and, by extension, these concentrated funds.
The two funds have tended to move in the same direction but with different amplitudes. SBIO’s emphasis on small- and mid-cap Phase II/III names often magnifies both gains and losses compared with XBI’s broader equal-weighted mix. XBI’s inclusion of large-cap names with recurring revenue, such as AMGN, BIIB, and GILD, adds a layer of earnings stability that SBIO does not have. In risk-on environments driven by deals or positive trial data, SBIO’s higher-beta stance can lead; in risk-off periods tied to higher rates or tighter financing, XBI’s diversification has historically helped moderate volatility. This difference in positioning remains central to the comparison.
When comparing sector ETFs like these, I turn to Tickeron’s AI Screener to quickly filter holdings by market cap, volatility, and technical patterns. It helps surface how the two funds stack up against broader industry peers without manual screening. From what I see, this kind of tool adds efficiency when evaluating structural differences in cost, liquidity, and diversification.
Based on structural factors rather than recent price moves, the AI analysis points to XBI over SBIO at present. XBI offers the lower expense ratio, wider diversification across about 166 holdings, equal-weight construction that reduces concentration risk, and stronger liquidity. Although SBIO’s clinical-stage focus can produce stronger momentum in biotech rallies, its narrower scope and higher costs increase sensitivity to drawdowns. Overall, the advantages in cost efficiency, diversification, and liquidity make XBI the more resilient choice for broad biotechnology exposure.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
XBI saw its Momentum Indicator move below the 0 level on November 11, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned negative. In 82 of the 91 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for XBI turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 48 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
XBI moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for XBI crossed bearishly below the 50-day moving average on November 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for XBI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 295 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows